Media

I

Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape

I

Who is ELAINE ?

I

Patient Story: Silke | Tempus

Silke describes her cancer journey from diagnosis through various treatments, including a clinical trial in which Tempus’ TIME Trial Program activated a trial site specifically for her at a clinic closer to home.

I

Lessons My Patients Taught Me

In the 10th podcast episode, Dr. Elliott Davidson describes how his patients and his beloved sister taught him different ways to beat cancer.

I

Future Directions of Lasofoxifene Research in Breast Cancer

I

Durable CR With Lasofoxifene in ESR1+, ER+/HER2- Metastatic Breast Cancer

I

ELAINE-1 Trial Examines Lasofoxifene in ESR1+, ER+/HER2- Breast Cancer

b

Phase 2 Data Support Development of Lasofoxifene in ESR1-mutant, ER+/HER2– Breast Cancer

b

Emerging ESR1-Targeted Therapy Added to Abemaciclib to Treat Metastatic ER+/HER2– Breast Cancer

b

ELAINE-3 Study of Lasofoxifene Initiates for ESR1-Mutated ER+/HER2- Breast Cancer

I

Dr. Damodaran on the ELAINE-2 Trial of Lasofoxifene/Abemaciclib in ESR1-Mutated, ER+/HER2- Breast Cancer

I

The Onco'Zine Brief

Candid Conversations on Mets, Sex, and Side Effects: a Panel Discussion With Breast Cancer Oncologists, Women’s Health Experts and Patients.

b

A Bench-to-Bedside Story

You can count on one hand the number of times a young graduate student finds a drug, then the drug is patented, licensed, and in a phase 2 trial within a couple years.
b

Article in Springer Nature

Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.